NCT03098121View on ClinicalTrials.gov

Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Chronic Hepatitis C
Interventions
DRUG

grazoprevir and elbasvir

For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.

Trial Locations (1)

33004

Taoyuan general hospital, Taoyuan District

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Taoyuan General Hospital

OTHER_GOV

NCT03098121 - Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection | Biotech Hunter | Biotech Hunter